Immunochina is based in Beijing, China. It has raised $45M in total funding. Latest round: Series C.
Immunochina funding overview
Immunochina is based in Beijing, China. Immunochina has raised $45M in total disclosed funding. That places its disclosed total in the $25M–$100M range. Its most recent disclosed round is a Series C announced in January 2019. The round record for Immunochina runs through 2019; nothing later has been disclosed. Investors on record include Shougang Fund, Sherpa Venture Capital, Peter Thiel, Qingzhe Capital, China Resources Innovative Equity Investment Fund. 5 distinct backers are named across the disclosed rounds.
Immunochina at a glance
Total raised
$45M
Latest round
Series C
Latest round date
January 2019
Headquarters
Beijing, China
Notable investors
Shougang Fund, Sherpa Venture Capital, Peter Thiel, Qingzhe Capital, China Resources Innovative Equity Investment Fund
Frequently asked about Immunochina funding
How much has Immunochina raised?
Immunochina has raised $45M in total disclosed funding across the rounds on record.
Who has invested in Immunochina?
Shougang Fund, Sherpa Venture Capital, Peter Thiel, Qingzhe Capital, China Resources Innovative Equity Investment Fund are named among the investors backing Immunochina.
What was the latest Immunochina funding round?
The most recent disclosed round is a Series C, announced in January 2019.
Where is Immunochina based?
Immunochina is based in Beijing, China.
When did Immunochina last raise?
The last disclosed Immunochina round closed in January 2019 at Series C.
Totals shown for Immunochina aggregate every disclosed round on file. To see how that compares, browse the companies in Beijing and the investors behind them below.
